Evidence map›Paper›PMID 33748269›Full record

ArticleBioMed research international2021

Network Pharmacological Study of

Liying Wu, Youguo Hao, Chuanqiang Dai, Zhibang Zhang, Munazza Ijaz, Sobhy M Ibrahim, Ghulam Murtaza, Zhiguang Yao

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 8 institutions in 3 countries.

Liying WuDepartment of Orthopedics, Fushun Mining Bureau General Hospital of Liaoning Health Industry Group (The Seventh Affiliated Hospital of China Medical University), Fushun, Liaoning 113008, China.
Youguo HaoDepartment of Rehabilitation, Shanghai Putuo People's Hospital, Shanghai 200060, China.
Chuanqiang DaiDepartment of Orthopedics, The First People's Hospital of Ziyang, Ziyang, Sichuan 641300, China.
Zhibang ZhangDepartment of Bone and Joint Surgery, Qinghai Fifth People's Hospital, Xining, Qinghai 810007, China.
Munazza IjazInstitute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.
Sobhy M IbrahimDepartment of Biochemistry, College of Science, King Saud University, P.O. Box: 2455, Riyadh 11451, Saudi Arabia.
Ghulam MurtazaDepartment of Pharmacy, COMSATS University Islamabad, Lahore Campus, Lahore 54000, Pakistan.
Zhiguang YaoGraduate School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China.ORCID https://orcid.org/0000-0002-3827-9380
Central Hospital of Putuo District · CNCOMSATS University Islamabad · PKKing Saud University · SALiaoning Shihua University · CNQinghai No.3 People's Hospital · CNThe First People's Hospital of Guiyang · CNUniversity of Lahore · PKZhejiang Chinese Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBone trauma is a clinical condition that afflicts the majority of the world's population. For the management of bone trauma, the underlying mechanisms of the drugs effective for bone healing are deemed necessary.

methodsAn extensive survey of published works led to the development of a drug-target database, after which multiple protein targets for bone trauma were discerned. The protein-protein interaction network was developed by utilizing the STITCH database and gene ontology (GO) enrichment analysis using Cytoscape and ClueGO. Moreover, docking studies were performed for revealing the affinity of various ingredients with IL6.

resultsThe extensive literature survey yielded the presence of 176 components in ABR, and 151 potential targets were acquired. Scrutinization of these targets revealed that 21 potential targets were found to be associated with bone trauma. Out of which, some remarkable targets such as IL6, MAPK14, MAPK8, SRC, PTGS2, and MMP2 were observed to be associated in the functional interaction of ABR. According to docking results, several ingredients of ABR such as Baicalien, Copistine, Epiberberine, Kaempferol, and Palmatine have the lowest docking scores (range between -6 and -7).

conclusionsThe results of the study elucidated that ABR can positively be utilized for the management of bone trauma, which can be mediated by multiple molecular mechanisms such as ERBB2 signaling pathway, positive regulation of oxidoreductase activity, JNK cascade pathway, multicellular organism metabolic process, T cell costimulation, and the positive regulation of MAPK activity. The findings also suggest that several ingredients of ABR such as Baicalien, Copistine, Epiberberine, Kaempferol, and Palmatine have good affinity with IL6, suggesting the promising potential of ABR in treating bone trauma, likely through IL6.

Indexed as

Databases, PharmaceuticalMolecular Docking SimulationBone DiseasesDrugs, Chinese HerbalGene OntologyHumansDrugs, Chinese Herbal

Identifiers

PMID33748269
PMCPMC7959927
OpenAlexW3133611757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.